Enter the first few characters of Company and click 'Go'

Nutraplus India Ltd. Company History and Annual Growth Details

NUTRAPLUS PRODUCTS (INDIA) LIMITED was originally incorporated as a private limited company on 6th February 1990 with the Registrar of Companies, Maharashtra at Bombay. It was subsequently converted into a Public Limited Company with effect from 13th June 1992 in terms of the resolution passed in the Extra Ordinary General Meeting of the Company held on 28th May 1992.

The Company is implementing a project for the manufacture of veterinary bulk drugs namely Dimetridazole (DMZ) and Dinitolmide (DOT) at M.I.D.C., Tarapur. Initially the Company proposed to set up manufacturing facilities for manufacture of Methyl Nitro Imidazole, an intermediate of DMZ with installed capacity of 240 MT per annum at a cost of Rs.123.66 Lakhs, for which it was sanctioned a term Loan of Rs.60 Lakhs from Maharashtra State Financial Corporation (MSFC).

But now the Company has decided to go in for production of Dimetridazole (DMZ) and Dinitolmide (DOT) with installed capacities of 160 MT and 300 MT respectively per annum due to high value addition in these products, than their intermediates, huge demand and export potential for these products, being veterinary bulk drugs and there being few units manufacturing these bulk drugs in the organised sector and also because these products are not under any government controls with regard to manufacturing, pricing, selling or distribution unlike other bulk drugs.

2014
-Company has changed its name from Nutraplus Products (India) Ltd to Nutraplus India Ltd.

2015
-The Company have opened a corporate office Nutraplus India Limited 201/202, 2nd Floor, Planet Industrial Estate, Subhash Road, Vile Parle (East), Mumbai - 400057. Whereas the Registered Office of the Company will remain the same i.e.:Nutraplus India Limited,Vakil Villa, 7-A, Society Road End, Jogeshwari (E), Mumbai - 400060

2016
-Nutraplus India as commenced commercial production in its new plant at Tarapur for anti-malarial drug LUMEFANTRINE.

Disclaimer: This is 3rd Party content/feed, viewers are requested to use their discretion and conduct proper diligence before investing, GoodReturns does not take any liability on the genuineness and correctness of the information in this article